DarioHealth

Overview
Activities
News
Preventive Healthcare?
Product stageSegments
Growth
?
Digital Therapeutics (DTx)
?

DarioHealth is a global digital therapeutics company that provides personalized programs, evidence-based interventions, and one-on-one coaching support to help patients manage chronic conditions and improve their overall health. The company has four programs covering diabetes and weight management, behavioral health, hypertension, and musculoskeletal (MSK) issues. 

These programs are delivered through a single mobile app and accompanying FDA-approved proprietary medical devices including a blood glucose monitoring kit, a pocket-sized smartphone glucometer, and a blood pressure monitoring system. The app curates personalized plans using AI technology and billions of behavioral data points from its members. 

The company began operating in the D2C market with a subscription-based business model. The company offers a three-tiered membership plan depending on the services offered. It later entered the B2B2C market consisting of employers, healthcare providers, and health plans. The company had 100 B2B contracts in total as of May 2023. Further, DarioHealth was available in the US, Canada, the UK, Germany, Italy, Australia, the Netherlands, and New Zealand.

The company made several acquisitions, including; 1) acquired Upright Technologies to launch its digital physical therapy platform, Dario Move (January 2021), 2) acquired WayForward to expand its mental health foothold (May 2021), 3) acquired Physimax to bolster its MSK capabilities ( January 2022 ), and 4) acquired Twill to expand its offerings ( February 2024 ).

For FY2023 , the company reported revenue of USD 20.4 million (down 26% YoY), while operating losses reduced by USD 0.6 million YoY to USD 56.2 million. 

Key customers and partnerships

The company has several key partnerships including; 1) Sanofi, to enter into a USD 30 million multi-year strategic collaboration to expand its market reach within the US ( March 2022 ), 2) Dexcom to add continuous glucose monitoring to its platform ( February 2023 ), and 3) Amwell Health to offer cardiometabolic solutions, starting in the 2H 2023 ( March 2023 ). 

HQ location:
142 W. 57th Street 8th Floor New York NY USA
Founded year:
2011
Employees:
251-500
IPO status:
Public
Total funding:
USD 255.7 mn
Last Funding:
USD 22.4 mn (Post IPO Equity; Dec 2023)
Last valuation:
-
Key competitors
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.